Navigation Links
MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada
Date:7/9/2008

TORONTO, July 9 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today announced that it has served Atomic Energy of Canada Limited (AECL) with notice of arbitration proceedings. MDS will be seeking an order to compel AECL to fulfill its contractual obligations under its 2006 interim and long-term supply agreement (ILTSA) and if not granted, seeking significant monetary damages. MDS has concurrently filed a court claim for $1.6 billion in damages against AECL, for negligence and breach of contract, and against the Government of Canada, for inducing breach of contract and for interference with economic relations.

"We have had to resort to taking these steps to protect the interests of patients, the nuclear medicine community, our shareholders and our customers," said Stephen P. DeFalco, President and CEO, MDS Inc. "We are disappointed that AECL and the Government decided to abandon the MAPLE project without establishing a clear plan for the long-term supply of critical medical isotopes."

MDS's primary objective through the legal proceedings is to have AECL honour its long standing commitment to replace the National Research Universal (NRU) reactor by bringing the MAPLE reactors into service, and provide a 40-year supply of medical isotopes, required by patients worldwide for serious medical needs.

In 1996, MDS entered into an agreement with AECL for the design, development and construction of two new nuclear reactors and a processing facility, known as the MAPLE project. The project was intended to replace AECL's NRU reactor, which produces approximately 50 per cent of the world's medical isotopes. AECL agreed to provide interim supply of medical isotopes from NRU until the MAPLE project was operational. The MAPLE project was to be completed by the year 2000 at a planned cost to MDS of $145 million.

By 2005, the project was not yet completed and
'/>"/>

SOURCE MDS Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Sun Pharma Commences All Cash Tender Offer to Purchase Taro Ordinary Shares for USD 7.75 Per Share
2. uKarma Corporation Commences International Distribution Agreement With Northern Response for its Xflowsion DVD Series
3. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
4. China Sky One Medical, Inc. Commences Trading on the American Stock Exchange
5. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
6. SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc.
7. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
8. Cytopia Commences Phase II Cancer Drug Study
9. Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
10. American Physicians Capital, Inc. Completes $15 Million Authorization and Commences $20 Million Authorization Under Stock Repurchase Program
11. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...ment. What do you remember about your breakfast th... smell of coffee brewing, while another will remem...r. How does the brain weave together these fragmen...ife? , Researchers led by Prof. Itzhak Fried, a ...lty of Medicine, are proving scientifically what s...
(Date:12/4/2008)...ird of Americans with diabetes do not know that th...ditions are unaware that they are at risk. A Univ...al tool to identify those at highest risk for havi...ose (IFG) and undiagnosed diabetes. If these condi...rom preventative strategies that can minimize prog...
(Date:12/4/2008)...c. 4 Triple-S,Managemen...it has signed a non-,binding letter of intent to ...zul de Puerto Rico, Inc. In addition, the Company...transfer the licensing rights to the Blue Cross br...ield brands in the US Virgin Islands,to the Compa...
(Date:12/4/2008)...work(TM) to Administer Program , , BUFFALO,...inder(TM) Network has been selected by The Washing...r a Medication Therapy Management (MTM) program fo...UMP) and the Aetna Public Employees Plan of Washin...mmunity pharmacists to review prescriptions with p...
Breaking Medicine News(10 mins):Health News:Unlocking the mysteries of memory 2Health News:Researcher develops screening tool to identify patients with prediabetes 2Health News:Triple-S Management Corporation Signs Letter of Intent to Acquire Managed Care Portfolio of La Cruz Azul de Puerto Rico, Inc. 2Health News:Washington State Health Care Authority to Launch Medication Therapy Management Initiative 2
...n babies and birth weight, it has been found that ...creased liking for salt.// The results of the pres...uals include more salt in their diet than others. ...lthy babies, weighing atleast 2.5 kg. These babies...
... of mothers who are obese before pregnancy or who ...ming overweight at a very young age//. The resea...s the children get older, in a research paper publ.... Dr. Pamela J. Salsberry and Dr. Patricia B. Re...
...ronique Roger, M.D., M.P.H., at the Mayo Cardiolog...e is a high risk of these patients suffering from ...ke risk was 44 times more during the 30 day period...ents when compared to the normal person. The study...
...om color blindness due to X-chromosome variations,...olors but have an increased sensitivity to differe... be differentiated by normal persons. The results ...llon and colleagues, University of Cambridge had b...
Other Medicine News:Health News:Birth Weight of Babies Important Predictor for Salt Preference 2Health News:Kids of overweight mothers have higher obesity risk 2Health News:Colorblind Individuals have expanded color vision 2
(Date:12/3/2008)... Pa., Dec. 3 Wyeth Pharm...nnounced today that it has submitted a,marketing ...dicines Agency,(EMEA) for approval to market its ...vaccine (PCV13) for infants and young children. W...of pneumococcal disease (PD) caused by the 13,ser...
(Date:12/2/2008)... 3 Researchers using fu...uitry in the area of the brain,responsible for su...ering from,stress-related psychiatric disorders. ...he annual meeting of the Radiological Society of N...major depression and other stress-related disorder...
(Date:12/2/2008)... Dec. 2 Horizon Therapeutics, Inc....ay announced that two pivotal,Phase 3 trials eval... HZT-501,met all primary endpoints. HZT-501, a n...containing ibuprofen and famotidine, demonstrated ...dence of non-steroidal,anti-inflammatory drug (NS...
(Date:12/1/2008)...c. 1 TargeGen has announced that a...a multi-center, US-based clinical,trial of TG1013... scheduled at,the 2008 American Society of Hemato...entation are as follows:, Title: ...ble, JAK2-Selective Inhibi...
Breaking Medicine Technology:Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac 28TM 29 Development at Prestigious International Sympos 2209 1Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac 28TM 29 Development at Prestigious International Sympos 2209 2Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac 28TM 29 Development at Prestigious International Sympos 2209 3Looking tired or angry may have more to do with facial aesthetics than how you feel 20399 1Looking tired or angry may have more to do with facial aesthetics than how you feel 20399 2Oregon Cosmetic Vein Center Opens in Portland Among First on West Coast to Offer Brand New FDA Approved Procedures and Technologies 20397 1Oregon Cosmetic Vein Center Opens in Portland Among First on West Coast to Offer Brand New FDA Approved Procedures and Technologies 20397 2Oregon Cosmetic Vein Center Opens in Portland Among First on West Coast to Offer Brand New FDA Approved Procedures and Technologies 20397 3Buyers Health Care Action Group Pilots New Bridges to Excellence Program for Depression 20395 1Buyers Health Care Action Group Pilots New Bridges to Excellence Program for Depression 20395 2Buyers Health Care Action Group Pilots New Bridges to Excellence Program for Depression 20395 3
...Mar 7, 2007 - Accentia,Biopharmaceuticals, Inc. (N...l Meeting of the American Academy of Allergy, Asth...San Diego, CA. The,posters discussed findings from...rgists in the U.S., U.K., France, and Germany on t... and attitudes of,the fungal etiology of CS, and t...
...r 7, 2007 - BioLineRx Ltd.,(TASE:BLRX), Israel,s l...e-clinical data from trials of BL-1040 demonstrati...ration of the myocardium,after a myocardial infarc...ion and eventual heart failure in a pig model. Pro...Cardiac Research,Institute at Sheba Medical Center...
Other Medicine Technology:Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 2Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 3Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 4Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 5BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 2BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 3
... F 265 is a highly accurate portable, waterproof s...e measurements. Temperature compensated pH results...e (ATC) or a 3-in-1 electrode. • This GLP/GMP...connect to a printer or a computer. Up to 100 data...
... F 255 is a portable, waterproof system for routin...ements. Temperature compensated pH results can be ...or a 3-in-1 electrode. • Fast and easy one-, ...tomatic buffer recognition for five buffers (pH 1....
... F 295 is a fully equipped, waterproof system for ... temperature measurements. Temperature compensated...rature probe (ATC) or a 3-in-1 electrode. Up to fi...MP compliant system includes an RS-232 interface t...
...lide doors, 8 shelves. Over-sized compressor. T...uorescent interior lighting. Self-Contained Syste...rd. Full One Year Warranty on Parts & Labor and a... available as a chromatography unit which includes...
Medicine Products: